Tibolone and Breast Tissue: a Review

Area of Science:

• Reproductive Endocrinology
• Oncology
• Pharmacology

Background:

• Hormone replacement therapy (HRT) safety for breast tissue remains a topic of debate.
• Tibolone is prescribed for menopausal symptom management in postmenopausal women.
• The specific impact of tibolone on breast health requires further clarification.

Purpose of the Study:

• To provide an updated review on tibolone's effects on breast tissue.
• To analyze preclinical and clinical data on tibolone's impact on breast density and cancer risk.
• To enhance clinician awareness regarding tibolone's breast safety profile for improved menopausal symptom management.

Main Methods:

• Narrative review of major preclinical and clinical studies.
• Analysis of data concerning tibolone's effects on breast tissue and density.
• Evaluation of studies investigating the relationship between tibolone and breast cancer risk.

Main Results:

• Tibolone use in postmenopausal women appears to have a generally safe profile concerning breast tissue.
• Available data suggest no significant adverse effects on breast density.
• Current evidence does not indicate an increased risk of breast cancer associated with tibolone.

Conclusions:

• Tibolone demonstrates a potentially favorable safety profile for breast tissue in postmenopausal women.
• Further research and ongoing monitoring are essential for comprehensive understanding.
• Clinicians can consider tibolone for menopausal symptom management with awareness of its current safety data.